Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437227 | 0.82 | MDM2 (0.67) | MDM2NOTUMALDH1A1HPGD | |
| SCHEMBL9894537 | 0.79 | MDM2 (0.68) | MDM2NOTUM | |
| SCHEMBL27862801 | 0.78 | MDM2 (0.78) | MDM2NOTUMRIPK1PLA2G2A | |
| SCHEMBL9894216 | 0.76 | MDM2 (0.50) | MDM2HPGDCTSA | |
| SCHEMBL9893712 | 0.75 | MDM2 (0.55) | MDM2NOTUMHPGDNPSR1 | |
| SCHEMBL1437320 | 0.73 | MDM2 (0.59) | MDM2NOTUM | |
| SCHEMBL9894477 | 0.72 | MDM2 (0.77) | MDM2NOTUMALDH1A1NPSR1 | |
| SCHEMBL9894082 | 0.72 | MDM2 (0.51) | MDM2NOTUMALDH1A1HPGD | |
| SCHEMBL1443240 | 0.71 | MDM2 (1.00) | MDM2NOTUMRIPK1 | |
| SCHEMBL1436964 | 0.71 | MDM2 (0.50) | MDM2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885NOTUM 4675/4885RIPK1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.